<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)</title>
	<atom:link href="http://www.myelomabeacon.com/news/2009/11/23/single-agent-actimid-and-combination-actimid-dexamethasone-regimens-are-promising-treatments-for-relapsed-multiple-myeloma-ash-2009/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.myelomabeacon.com/news/2009/11/23/single-agent-actimid-and-combination-actimid-dexamethasone-regimens-are-promising-treatments-for-relapsed-multiple-myeloma-ash-2009/</link>
	<description>The Myeloma Beacon provides extensive news, articles, and directories related to multiple myeloma. Its mission is to be the leading Internet resource for multiple myeloma patients, their families, and others interested in multiple myeloma.</description>
	<lastBuildDate>Thu, 25 Feb 2010 22:10:27 -0500</lastBuildDate>
	
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Jessica Langholtz</title>
		<link>http://www.myelomabeacon.com/news/2009/11/23/single-agent-actimid-and-combination-actimid-dexamethasone-regimens-are-promising-treatments-for-relapsed-multiple-myeloma-ash-2009/comment-page-1/#comment-1822</link>
		<dc:creator>Jessica Langholtz</dc:creator>
		<pubDate>Mon, 21 Dec 2009 15:41:47 +0000</pubDate>
		<guid isPermaLink="false">http://www.myelomabeacon.com/?p=8767#comment-1822</guid>
		<description>Dear Janice,

Actimid (pomalidomide) is still undergoing Phase 2 clinical trials for evaluation of its safety and efficacy for the treatment of multiple myeloma. A timeline has not yet been announced to indicate when Celgene, it&#039;s manufacturer, will apply for FDA approval.  We will keep you posted at The Myeloma Beacon when more information becomes known.

Best,
Jessica Langholtz</description>
		<content:encoded><![CDATA[<p>Dear Janice,</p>
<p>Actimid (pomalidomide) is still undergoing Phase 2 clinical trials for evaluation of its safety and efficacy for the treatment of multiple myeloma. A timeline has not yet been announced to indicate when Celgene, it&#8217;s manufacturer, will apply for FDA approval.  We will keep you posted at The Myeloma Beacon when more information becomes known.</p>
<p>Best,<br />
Jessica Langholtz</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: janice schmeeckle</title>
		<link>http://www.myelomabeacon.com/news/2009/11/23/single-agent-actimid-and-combination-actimid-dexamethasone-regimens-are-promising-treatments-for-relapsed-multiple-myeloma-ash-2009/comment-page-1/#comment-1812</link>
		<dc:creator>janice schmeeckle</dc:creator>
		<pubDate>Mon, 21 Dec 2009 01:06:03 +0000</pubDate>
		<guid isPermaLink="false">http://www.myelomabeacon.com/?p=8767#comment-1812</guid>
		<description>We have been reading about Pomalidomide for over two years.  Any idea as to when they will seek FDA approval and get it to market?  There are many people with MM that need this and other new meds to live.  

Tahnk you,

Janice Schmeeckle</description>
		<content:encoded><![CDATA[<p>We have been reading about Pomalidomide for over two years.  Any idea as to when they will seek FDA approval and get it to market?  There are many people with MM that need this and other new meds to live.  </p>
<p>Tahnk you,</p>
<p>Janice Schmeeckle</p>
]]></content:encoded>
	</item>
</channel>
</rss>
